Sanarus submits breast biopsy system to FDA:
This article was originally published in Clinica
Executive Summary
Sanarus Medical has filed a 510(k) approval application with the US FDA for its Core Tissue Biopsy System. The minimally invasive device is used to obtain biopsy samples from breast lesions and is based on cryosurgery and ultrasound guidance technology developed by Endocare, of Irvine, California. Sanarus of Pleasanton, California, and Endocare are jointly commercialising Endocare's cryosurgical technology for treating breast tumours and gynaecological diseases under an October 1999 agreement. Endocare also has a minority equity position in Sanarus, which plans to file additional applications in the coming months for complementary proprietary platforms for managing and treating different types of breast disease.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.